Previous Close | 2.8300 |
Open | 3.0000 |
Bid | 2.2500 x 900 |
Ask | 2.3500 x 900 |
Day's Range | 2.2500 - 2.8000 |
52 Week Range | 1.3600 - 10.6500 |
Volume | |
Avg. Volume | 66,535 |
Market Cap | 90.609M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9900 |
Earnings Date | Nov 09, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.50 |
Earlier today, Lucira Health released financial results for the second quarter ended June 30, 2022. Joining me on today's call are Erik Engelson, president and chief executive officer; and Dan George, chief financial officer.
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the seco
Insiders were net buyers of Lucira Health, Inc.'s ( NASDAQ:LHDX ) stock during the past year. That is, insiders bought...